Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies

R Duléry, E Brissot, M Mohty - Blood Reviews, 2023 - Elsevier
In search of an ideal partner or alternative to conventional immunosuppressive agents,
rabbit anti-thymocyte globulin (ATG) and, more recently, post-transplant cyclophosphamide …

Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies

R Mohty, R Dulery, AH Bazarbachi, M Savani… - Blood Cancer …, 2021 - nature.com
Hodgkin lymphoma is a highly curable disease. Although most patients achieve complete
response following frontline therapy, key unmet clinical needs remain including …

Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation

R Duléry, R Mohty, M Labopin, S Sestili, F Malard… - Cardio Oncology, 2021 - jacc.org
Background Post-transplant cyclophosphamide (PT-Cy) has become a standard of care in
haploidentical hematopoietic stem cell transplantation (HSCT) to reduce the risk of graft …

Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies

R Duléry, C Goudet, D Mannina, A Bianchessi… - Bone Marrow …, 2023 - nature.com
Although post-transplant cyclophosphamide (PT-Cy) is effective for graft-versus-host
disease (GVHD) prophylaxis, it is associated with toxicities, which might be dose-dependent …

Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation

H Guo, YJ Chang, Y Hong, LP Xu, Y Wang… - Cellular & molecular …, 2021 - nature.com
Haploidentical stem cell transplantation (haplo-SCT) achieves superior or at least
comparable clinical outcomes to HLA-matched sibling donor transplantation (MSDT) in …

Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation

R Duléry, F Malard, E Brissot, A Banet… - Bone Marrow …, 2023 - nature.com
Post-transplant cyclophosphamide (PT-Cy) is effective for graft-versus-host disease (GVHD)
prophylaxis, but it may cause dose-dependent toxicities, particularly in frail patients …

Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: a …

N Gagelmann, A Bacigalupo, A Rambaldi… - JAMA …, 2019 - jamanetwork.com
Importance Use of haploidentical (HAPLO) stem cell transplantation with posttransplant
cyclophosphamide is rapidly increasing in adults with hematologic cancers. However, its …

Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study

YJ Chang, Y Wang, LP Xu, XH Zhang, H Chen… - Journal of hematology & …, 2020 - Springer
Background Previous reports suggest a benefit associated with haploidentical donor
transplantation (HIDT) compared to matched sibling donor transplantation (MSDT) in certain …

Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide–based haploidentical versus matched sibling donor reduced-intensity …

S Ahmed, JA Kanakry, KW Ahn, C Litovich… - Biology of blood and …, 2019 - Elsevier
Classic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit
from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched …

Granulocyte colony-stimulating factor-primed unmanipulated haploidentical blood and marrow transplantation

YJ Chang, XY Zhao, XJ Huang - Frontiers in Immunology, 2019 - frontiersin.org
Granulocyte colony-stimulating factor (G-CSF), a growth factor for neutrophils, has been
successfully used for stem cell mobilization and T cell immune tolerance induction. The …